Salix Pharmaceuticals Ltd: Premium Company Profile

Publication Date	December 2007
Publisher	Datamonitor
Product Type	Databook
Pages	51
ISBN Number	not applicable
Product Code	DAT09433

Price

£265.00
approximately: $521 | €337

PRINT £265 ($521 | €337)

Order above formats by FAX

Summary

Introduction

Salix's main focus is to develop and market prescription drugs used in the treatment of various gastrointestinal diseases. Specifically, the company adopts in-licensing by entering into license and marketing agreements to acquire, develop and commercialize prescription drugs used in the treatment of gastrointestinal diseases.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Salix is a specialty pharmaceutical company engaged in the development, sale and marketing of prescription pharmaceuticals. The company has a portfolio of in-licensed products that includes: Anusol, Azasan, Colazal, MoviPrep, OsmoPrep, Pepcid, Proctocort, Visicol and Xifaxan.

Salix derives its revenues from product sales which mainly comprise of sales of its in-licensed products. The company's total revenues increased at a CAGR of 58.0% during 2002-2006, from $33 million to $209 million.

The company's biggest contributor to sales growth out to 2010 will be the sales of Colazal, used in pediatric patients between 5 to 17 years of age with ulcerative colitis Revenues from Colazal sales is expected to increase at a CAGR of 16%, from $104 million in 2006 to $185 million in 2010.

Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

Overview
Catalyst
- Summary
- Company Structure
- Company Overview and Key Facts
- Business Description
- History
- Company Financials
- Stock Market Performance
- P&L
- Balance Sheet
- Cash Flow
- Products & Services
- Marketed Products
- Pipeline Products
- Historical Product Sales
- AC Forecast Product Sales
- Competitors and Strategic Business Relationships
- Key Competitors
- Key Suppliers
- Key Clients
- Shareholding Structure
- Strategy
- Company View
- Corporate Strategy
- SWOT Analysis
- Overview
- Strengths
- Weaknesses
- Opportunities
- Threats
- Value Chain Analysis
Overview
- Product Development
- Manufacturing
- Sales
- Scorecard
- Overview
- Scorecard Analysis
- Key Employees
- List of Key Employees
- Key Employee Biographies
- Financial and Operational Overview
- Financial and Operational Overview
Appendix
- Ask the analyst
- Datamonitor consulting
- Disclaimer
- Figure 1: Salix - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
- Figure 2: Salix - Key Strategic Revenues, 2002-2006 ($ Mn)
- Figure 3: Salix - Key Strategic Revenues, 2006-2010 ($ Mn)
- Table 1: Salix - Key Facts
- Table 2: Salix - Year-End Share Price and Market Capitalization, 2002-2006 ($)
- Table 3: Salix - Key Events Impacting Share Price Performance
- Table 4: Salix - Operating Revenue / Cost Analysis, 2002-2006 ($Mn)
- Table 5: Salix - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
- Table 6: Salix - Balance Sheet, 2002-2006 ($ Mn)
- Table 7: Salix - Cash Flow, 2002-2006 ($ Mn)
- Table 8: Salix - Marketed Products
- Table 9: Salix - in-house Pipeline Products
- Table 10: Salix - Historical Product Sales, 2002-2006 ($ Mn)
- Table 11: Salix - Forecast Sales, 2006-2010 ($ Mn)
- Table 12: Salix - Key Competitors
- Table 13: Salix - Key Suppliers
- Table 14: Salix - Key Shareholders
- Table 15: Salix - SWOT Analysis Summary
- Table 16: Salix - Value Chain Analysis
- Table 17: Salix - Scorecard
- Table 18: Salix - Key Employees
- Table 19: Salix - Financial and Operational Overview